+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Nuclear Medicine Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4771722
  • Report
  • 112 pages
  • Mordor Intelligence
until Dec 31st 2019
1 of 5


  • Cardinal Health Inc.
  • Curium
  • Eczacibasi-Monrol
  • GE Healthcare
  • Iba Group
  • Lantheus Medical Imaging
  • MORE
Market Overview
  • Increasing incidences of cancer and cardiac ailments are the major drivers for the market studied. Nuclear medicine shows a huge potential in treating cardiac and cancer diseases. According to the National Cancer Institute (NCI) report, it was estimated that 1,735,350 new cases of cancer are diagnosed in the United States in 2018, and 609,640 people may die from the disease.
  • Other factors, such as increasing SPECT and PET applications and growing public awareness for healthcare, are expected to drive the market in the future. Regulatory requirements pose another hurdle to translational research and clinical investigations.
  • In the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radio therapeutics, undergo regulatory oversight by the FDA. Radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways. Sometimes, extensive toxicology testing poses considerable financial burdens for the investigators.
  • Additionally, reimbursement hurdles for the manufacturer and high capital investment are also restraining the market growth.
Scope of the Report

Nuclear medicine falls under the field of molecular imaging, which involves the use of a very small amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radioisotopes are detected by special types of cameras attached to the computer, which in turn, provide very precise pictures of the area of the body examined.

Key Market Trends

Cardiology Application is Expected to Experience Strong Growth in the Market

The application segment is further sub-segmented into cardiology, neurology, oncology, and other applications. The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases (CVD) over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died, due to CVDs.

The diagnostics segment is further segmented into SPECT and PET. PET imaging radioisotopes have many applications in clinical neurology, which involves movement disorders, epilepsy, brain tumors, dementia, stroke, and neuronal plasticity. Future applications include early diagnosis of brain metastases, Parkinson syndromes, and neurodegenerative disorders, such as Alzheimer's disease. The market for radioisotopes is expected to be larger in the developing countries because of the increasing awareness among people about radioisotopes, increasing the incidence of chronic diseases, like cancer, and increasing population.

North America is Expected to Dominate the Nuclear Medicine Market

North America is the dominant market for nuclear medicine. Within North America, the United States is the largest consumer market for radioisotopes, and Canada is the largest producer of Tc-99m. The United States was the largest contributor to the North American region, in terms of revenue, and it is expected to retain its dominance, owing to the higher procedural volume and increasing adoption of nuclear medicine for various therapeutic applications.

Asia-Pacific is expected to witness healthy CAGR during the forecast period. A rise in demand for nuclear medicines in emerging countries, such as India and China, is due to the rise in disposable income, improving healthcare standards, and favorable reforms in foreign policies.

Competitive Landscape

There is high competition among the players of the global nuclear medicine market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. For instance, April 2017, IBA Molecular and Mallinckrodt Nuclear Medicine LLC united to create Curium, a world-class provider in nuclear imaging. Various developments have recently been taking place in the market, such as and in May 2018, Curium enhanced its position in the French PET market with the acquisition of Cyclopharma’s French commercial and manufacturing operations.
Note: Product cover images may vary from those shown
2 of 5


  • Cardinal Health Inc.
  • Curium
  • Eczacibasi-Monrol
  • GE Healthcare
  • Iba Group
  • Lantheus Medical Imaging
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Several Blockbuster Biopharmaceuticals Going Off-patent over the Next Five to Ten Years
4.2.2 Market in the Nascent Phase but with High Growth Potential
4.2.3 Increasing Demand for Biosimilar Drugs due to Their Cost Effectiveness
4.3 Market Restraints
4.3.1 Concerns Regarding Substitutability and Interchangeability
4.3.2 Regulatory Uncertainty
4.3.3 Production Complexity
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Diagnostics
5.1.1 SPECT Market
5.1.2 PET
5.2 Therapeutics
5.2.1 Alpha Emitters
5.2.2 Beta Emitters
5.2.3 Brachytherapy
5.3 Application
5.3.1 Cardiology
5.3.2 Neurology
5.3.3 Oncology
5.3.4 Other Applications
5.4 Geography
5.4.1 North America US Canada Mexico
5.4.2 Europe Germany UK France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Mallinckrodt
6.1.2 Lantheus Medical Imaging
6.1.3 Iba Group
6.1.4 Triad Isotopes
6.1.5 Siemens Healthcare
6.1.6 Advanced Accelerator Applications
6.1.7 Curium
6.1.8 Cambridge Isotope Laboratories Inc.
6.1.9 Cardinal Health Inc.
6.1.10 GE Healthcare
6.1.11 Nordion Inc.
6.1.12 Taiyo Nippon Sanso Corporation
6.1.13 Fujifilm Holdings Corporation
6.1.14 Eczacibasi-Monrol
6.1.15 Isotec Inc. (Sigma-Aldrich)

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Mallinckrodt
  • Lantheus Medical Imaging
  • Iba Group
  • Triad Isotopes
  • Siemens Healthcare
  • Advanced Accelerator Applications
  • Curium
  • Cambridge Isotope Laboratories Inc.
  • Cardinal Health Inc.
  • GE Healthcare
  • Nordion Inc.
  • Taiyo Nippon Sanso Corporation
  • Fujifilm Holdings Corporation
  • Eczacibasi-Monrol
  • Isotec Inc. (Sigma-Aldrich)
Note: Product cover images may vary from those shown
5 of 5